Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia
Autore:
Agis, H; Weltermann, A; Mitterbauer, G; Thalhammer, R; Edelhauser, M; Seewann, HL; Valent, P; Lechner, K; Fonatsch, C; Geissler, K;
Indirizzi:
Univ Vienna, Allgemeines Krankenhaus Wien, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 & Hemostaseol, A-1090 Vienna, Austria Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 , Dept Lab Med, A-1090 Vienna, Austria Univ Vienna, Inst Med Biol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 Inst Med Biol, A-1090 Vienna, Austria Lkh Furstenfeld, Dept Med, A-8280 Furstenfeld, Austria Lkh Furstenfeld Furstenfeld Austria A-8280 , A-8280 Furstenfeld, Austria
Titolo Testata:
ANNALS OF HEMATOLOGY
fascicolo: 7, volume: 78, anno: 1999,
pagine: 329 - 332
SICI:
0939-5555(199907)78:7<329:STWATO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
RETINOIC ACID; CELLS; REMISSION; AS2O3;
Keywords:
acute myeloid leukemia; acute promyelocytic leukemia; treatment; ATRA; arsenic trioxide;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
14
Recensione:
Indirizzi per estratti:
Indirizzo: Agis, H Univ Vienna, Allgemeines Krankenhaus Wien, Dept Internal Med 1, Div Hematol & Hemostaseol, Wahringer Guertel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Guertel 18-20 Vienna Austria A-1090 Austria
Citazione:
H. Agis et al., "Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia", ANN HEMATOL, 78(7), 1999, pp. 329-332

Abstract

Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia (APL). In the present study, arsenic trioxide was given intravenously for 42 days to a 56-year-old female patient suffering from chemotherapy/ATRA-resistant APL, with 43% APL blasts in the bone marrow and elevated D-dimers. During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes. This initial coagulation response was followed by a second phase of hematological response (starting on days 15-20) characterized by leukocytosis, occurrence of myeloid progenitor cells in the peripheral blood,and a decrease in bone marrow blasts (<1% on days 28 and 36). Finally, thepatient entered complete hematological and cytogenetic remission, althoughthe PML-RAR alpha fusion product was still detectable by PCR. These data confirm the therapeutic value of arsenic trioxide in relapsed/resistant APL.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 05:13:08